Absence of Proteinuria Predicts Improvement in Renal Function After Conversion to Sirolimus-based Immunosuppressive Regimens in Lung Transplant Survivors With Chronic Kidney Disease

Journal of Heart and Lung Transplantation

Volumn 28, Issue 6, 2009, Pages 564-571

  Stephany, Brian R ^a   Boumitri, Mirna ^a   Budev, Marie ^a   Alao, Bashar ^b   Poggio, Emilio D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; AGED; CALCINEURIN; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEINURIA; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 65749105204     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.03.010     Document Type: Article

References (43)

1. Miller B.W. Chronic kidney disease in solid-organ transplantation. Adv Chronic Kidney Dis 13 (2006) 29-34
2. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
3. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
4. Stephany B.R., Alao B., Budev M., et al. Hyperlipidemia is associated with accelerated chronic kidney disease progression after lung transplantation. Am J Transplant 7 (2007) 2553-2560
5. Barraclough K., Menahem S.A., Bailey M., et al. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant 25 (2006) 1431-1435
6. Andoh T.F., Burdmann E.A., Fransechini N., et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50 (1996) 1110-1117
7. Augustine J.J., Bodziak K.A., and Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 67 (2007) 369-391
8. Augustine J.J., Chang P.C., Knauss T.C., et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 81 (2006) 1004-1009
9. Lieberthal W., Fuhro R., Andry C.C., et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281 (2001) F693-F706
10. McTaggart R.A., Gottlieb D., Brooks J., et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3 (2003) 416-423
11. Shihab F.S., Bennett W.M., Yi H., et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65 (2004) 1262-1271
12. Diekmann F., and Campistol J.M. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21 (2006) 562-568
13. Diekmann F., Waiser J., Fritsche L., et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 33 (2001) 3234-3235
14. Dominguez J., Mahalati K., Kiberd B., et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70 (2000) 1244-1247
15. Schena F., Vitko S., Wali R., et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18-month results from a randomized, open-label comparative trial. [Abstract]. J Am Soc Nephrol 17 (2006) 1026A
16. Wyzgal J., Paczek L., Senatorski G., et al. Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 34 (2002) 3185-3187
17. Formica Jr. R.N., Lorber K.M., Friedman A.L., et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 35 suppl (2003) 95S-98S
18. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777-786
19. Gonwa T.A., Hricik D.E., Brinker K., et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74 (2002) 1560-1567
20. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75 (2003) 1404-1408
21. Stallone G., Di Paolo S., Schena A., et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 75 (2003) 998-1003
22. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76 (2003) 364-370
23. Mulay A.V., Hussain N., Fergusson D., et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5 (2005) 1748-1756
24. Watson C.J., Firth J., Williams P.F., et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5 (2005) 2496-2503
25. Fairbanks K.D., Eustace J.A., Fine D., et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transplant 9 (2003) 1079-1085
26. Kniepeiss D., Iberer F., Grasser B., et al. Sirolimus and mycophenolate mofetil after liver transplantation. Transplant Int 16 (2003) 504-509
27. Trotter J.F., Wachs M., Bak T., et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transplant 7 (2001) 343-351
28. Groetzner J., Meiser B., Landwehr P., et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77 (2004) 568-574
29. Groetzner J., Wittwer T., Kaczmarek I., et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 81 (2006) 355-360
30. Lischke R., Simonek J., Matousovic K., et al. Initial single-center experience with sirolimus after lung transplantation. Transplant Proc 38 (2006) 3006-3011
31. Shitrit D., Rahamimov R., Gidon S., et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int 67 (2005) 1471-1475
32. Snell G.I., Levvey B.J., Chin W., et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc 33 (2001) 1084-1085
33. Snell G.I., Levvey B.J., Chin W., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 21 (2002) 540-546
34. Ussetti P., Laporta R., de Pablo A., et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 35 (2003) 1974-1977
35. Venuta F., De Giacomo T., Rendina E.A., et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 78 (2004) 1940-1943
36. Levey A., Greene T., Kusek J., et al. A simplified equation to predict glomerular filtration rate from serum creatinine. [Abstract]. J Am Soc Nephrol 11 (2000) 155A
37. Disease KDCPGoCK, Group W. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39 suppl 1 (2002) S46
38. Srinivas T.R., Schold J.D., Guerra G., et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 7 (2007) 586-594
39. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5 (2005) 2273-2280
40. Campistol J., Oberbauer R., Schena F., et al. Univariate and multivariate analyses of factors affecting renal allograft function after conversion from calcineurin inhibitor (CI)- to sirolimus (SRL)-based immunosuppression: results from the multicenter CONVERT trial. [Abstract]. J Am Soc Nephrol 17 (2006) 1025A
41. Iseki K., Ikemiya Y., Iseki C., and Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63 (2003) 1468-1474
42. Stephany B.R., Augustine J.J., Krishnamurthi V., et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 82 (2006) 368-374
43. Demirjian SSB, Abu Romeh IS, Boumitri M, et al. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Clin Transplant (in press).